These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10484547)

  • 21. Vasovagal syncope: an update on the latest pharmacological therapies.
    Schleifer JW; Shen WK
    Expert Opin Pharmacother; 2015 Mar; 16(4):501-13. PubMed ID: 25534874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current management of syncope : focus on drug therapy.
    Venugopal D; Jhanjee R; Benditt DG
    Am J Cardiovasc Drugs; 2007; 7(6):399-411. PubMed ID: 18076207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial).
    Romme JJ; van Dijk N; Go-Schön IK; Reitsma JB; Wieling W
    Europace; 2011 Nov; 13(11):1639-47. PubMed ID: 21752826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. beta-adrenergic receptor blockers and the treatment of vasovagal syncope: more nails in the coffin!
    Mathias CJ
    Clin Sci (Lond); 2006 Sep; 111(3):189-91. PubMed ID: 16848762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological methods for the prevention of first and recurrent bleeding from esophagogastric varices.
    Fleig WE
    Z Gastroenterol; 1988 Sep; 26 Suppl 2():40-8. PubMed ID: 2903596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial.
    Sheldon R; Raj SR; Rose MS; Morillo CA; Krahn AD; Medina E; Talajic M; Kus T; Seifer CM; Lelonek M; Klingenheben T; Parkash R; Ritchie D; McRae M;
    J Am Coll Cardiol; 2016 Jul; 68(1):1-9. PubMed ID: 27364043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relationship between neurally mediated hypotension and the chronic fatigue syndrome.
    Bou-Holaigah I; Rowe PC; Kan J; Calkins H
    JAMA; 1995 Sep; 274(12):961-7. PubMed ID: 7674527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope.
    Sheldon R; Connolly S; Rose S; Klingenheben T; Krahn A; Morillo C; Talajic M; Ku T; Fouad-Tarazi F; Ritchie D; Koshman ML;
    Circulation; 2006 Mar; 113(9):1164-70. PubMed ID: 16505178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope.
    Scott WA; Pongiglione G; Bromberg BI; Schaffer MS; Deal BJ; Fish FA; Dick M
    Am J Cardiol; 1995 Aug; 76(5):400-2. PubMed ID: 7639169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neurally Mediated Syncope.
    Fabian WH; Benditt DG; Lurie KG
    Curr Treat Options Cardiovasc Med; 1999 Aug; 1(2):137-144. PubMed ID: 11096478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is there an effective pharmacological treatment in the prevention of vasovagal syncope?
    Sutton R
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():25-28. PubMed ID: 8734160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Worsening of vasovagal syncope after beta-blocker therapy.
    Wang CC; Yeh SJ; Wen MS; Lin FC; Wu D
    Chest; 1994 Sep; 106(3):963-5. PubMed ID: 7915980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of beta-adrenergic blockader therapy in vasovagal syncope reproduced by head-up tilt test].
    Blanc JJ; Corbel C; Mansourati J; Genet L
    Arch Mal Coeur Vaiss; 1991 Oct; 84(10):1453-7. PubMed ID: 1684700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management and therapy of vasovagal syncope: A review.
    Aydin MA; Salukhe TV; Wilke I; Willems S
    World J Cardiol; 2010 Oct; 2(10):308-15. PubMed ID: 21160608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Worsening of head-up tilt test response during chronic beta-blocker therapy in patients treated for neurally mediated syncope.
    Gardini A; Benedini G; Proto C
    G Ital Cardiol; 1998 Aug; 28(8):899-903. PubMed ID: 9773316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test.
    Sheldon R; Rose S; Flanagan P; Koshman ML; Killam S
    Am J Cardiol; 1996 Sep; 78(5):536-9. PubMed ID: 8806338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope.
    Gracie J; Newton JL; Norton M; Baker C; Freeston M
    Europace; 2006 Aug; 8(8):636-43. PubMed ID: 16864617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of migraine].
    Suomen Neurologinen yhdistys ry
    Duodecim; 2002; 118(11):1200-9. PubMed ID: 12269238
    [No Abstract]   [Full Text] [Related]  

  • 39. Failure of propranolol to prevent tilt-evoked systemic vasodilatation, adrenaline release and neurocardiogenic syncope.
    Eldadah BA; Pechnik SL; Holmes CS; Moak JP; Saleem AM; Goldstein DS
    Clin Sci (Lond); 2006 Sep; 111(3):209-16. PubMed ID: 16634720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic approaches to therapy for vasovagal syncope.
    Calkins H
    Am J Cardiol; 1999 Oct; 84(8A):20Q-25Q. PubMed ID: 10568557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.